1 – 10 of 89
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
TREM2 risk variants and associated endophenotypes in alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Differential effects of aging, Alzheimer's pathology, and APOE4 on longitudinal functional connectivity and episodic memory in older adults
(
- Contribution to journal › Article
-
Mark
evoke and evoke+ : design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Benchmarking Alzheimer’s disease prediction : personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies
(
- Contribution to journal › Article
-
Mark
Neuronal CD59 isoforms IRIS-1 and IRIS-2 as regulators of neurotransmitter release with implications for Alzheimer’s disease
(
- Contribution to journal › Article
- 2024
-
Mark
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
(
- Contribution to journal › Article
-
Mark
The impact of tau-PET in a selected memory clinic cohort : rationale and design of the TAP-TAU study
(
- Contribution to journal › Article
-
Mark
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
(
- Contribution to journal › Article
-
Mark
The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and App NL−F/NL−F mice
(
- Contribution to journal › Article
-
Mark
Rationale and design of the BeyeOMARKER study : prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic
(
- Contribution to journal › Article